ABR-Oligonucleotide

Developing Oligonucleotide Process for Large Scale Manufacturing

——

ABR is proud to announce the expansion of our services to include developing Oligonucleotide process for Large-Scale Manufacturing. This new offering is designed uniquely to meet the growing demand for oligonucleotide therapeutics, providing comprehensive support for the production of these complex molecules at commercial scale. Leveraging state-of-the-art technology in oligonucleotide synthesis, and based on rich experience at peptide purification, ABR is committed to delivering high-quality, scalable solutions that meet the specific needs of our clients in the pharmaceutical and biotechnology sectors.
With the introduction of developing Oligonucleotide process for Large-Scale Manufacturing, ABR is poised to play a pivotal role in advancing the field of oligonucleotide therapeutics. Whether you are in the early stages of development or ready for commercial-scale production, ABR is here to support your success.

The Rise of Oligonucleotide Therapeutics

Oligonucleotides has emerged as a promising class of drugs targeting a wide range of diseases at the genetic level. These therapies work by altering the expression of genes or the processing of their RNA transcripts, offering potential treatments for conditions that were previously considered untreatable. Among the various types of oligonucleotide therapies, Antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) are the two most widely used strategies for silencing (specifically reducing) gene expression, with several therapies already approved or in development. The development and commercialization of oligonucleotide drugs require specialized knowledge and capabilities in large-scale synthesis, purification, and quality control to ensure the delivery of safe, effective, and consistent products.

Why Work With ABR?

Facilities
ABR's facility will be equipped with the unique technologies for developing the oligonucleotide large-scale manufacturing. Our scalable processes are developed to support production from early clinical trials through to commercial launch and beyond, ensuring a reliable supply of high-quality oligonucleotides.

Capability
Our team of scientists and engineers brings extensive experience in oligonucleotide chemistry and manufacturing. With a deep understanding of the challenges and opportunities in oligonucleotide therapeutics, the limitation of common flow-through synthesizers exists, a scale of over 2 mol of oligonucleotide per batch is unprecedented. ABR is developing a unique manufacturing process based on our platform technology. This unique process is scalable, can be up to metric ton.